Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends
Authors:
- 9 February 2015
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (10) , 4131-4164
Abstract
Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chronic obstructive pulmonary disease (COPD). Among approved LAMA, tiotropium bromide, glycopyrronium bromide, and umeclidinium bromide are administered once daily, whereas aclidinium bromide is administered every 12 h. New LAMA are under development for COPD. Among the approved LABA, indacaterol has a 24 h duration of action, whereas salmeterol and formoterol require twice-daily administration. New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abediterol, are in development. LAMA/LABA fixed dose combinations (FDCs) provide the convenience of two bronchodilators with different mechanism of action in a single inhaler. Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been approved or are under approval and are likely to become a standard pharmacological strategy for COPD. Inhaled dual-pharmacology compounds, combining muscarinic antagonism and β2-agonism (MABA) in a single molecule, potentially provide additive or synergistic bronchodilation over either inhaled antimuscarinic or β2-agonist monotherapy.Keywords
This publication has 173 references indexed in Scilit:
- Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPDPulmonary Pharmacology & Therapeutics, 2013
- Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPDPulmonary Pharmacology & Therapeutics, 2013
- Pharmacological Characterization of Abediterol, a Novel Inhaled β2-Adrenoceptor Agonist with Long Duration of Action and a Favorable Safety Profile in Preclinical ModelsThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsBMJ, 2011
- Long‐lasting target binding and rebinding as mechanisms to prolongin vivodrug actionBritish Journal of Pharmacology, 2010
- Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialThe Lancet, 2009
- Molecular mechanisms for the persistent bronchodilatory effect of the β2‐adrenoceptor agonist salmeterolBritish Journal of Pharmacology, 2009
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2008
- Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary DiseaseJAMA, 2008
- Tiotropium (SPIRIVA™): Mechanistical considerations and clinical profile in obstructive lung diseaseLife Sciences, 1999